Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.67 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.67 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | QPCT | Q16769 | 1/20 | 0.57 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.57 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729141 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL16160952 | 0.81 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL2529997 | 0.81 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL1024261 | 0.79 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL2033990 | 0.78 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.77 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL2729830 | 0.75 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL9369294 | 0.74 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL7284368 | 0.74 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL27457703 | 0.74 | MEN1 (0.60) | CYP11B1CYP11B2CYP17A1CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | claimed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | claimed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | claimed |
| EP-2018185-B1 | USE OF MAS-G-PROTEIN-COUPLED RECEPTOR AGONISTS IN THE TREATMENT OF THE METABOLIC SYNDROME, ITS COMPONENTS AND ITS COMPLICATIONS | UNIV MINAS GERAIS (BR) | 2016-08-31 | — | — | EP | claimed |
| US-20160074466-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | TARIX PHARMACEUTICALS LTD. | 2016-03-17 | — | — | US | claimed |
| CN-104302305-A | Angiotensins for treatment of fibrosis | TARIX PHARMACEUTICALS LTD | 2015-01-21 | — | — | CN | claimed |
| EP-2790716-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | Tarix Pharmaceuticals Ltd. (US) | 2014-10-22 | — | — | EP | claimed |
| US-20140073760-A1 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY | CHARITE-UNIVERSITATSMEDIZIN BERLIN (DE) | 2014-03-13 | — | — | US | claimed |
| WO-2013090833-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | TARIX PHARMACEUTICALS LTD. (US) | 2013-06-20 | — | — | WO | claimed |
| EP-2163259-B1 | Use of an Ang-(1-7) receptor agonist in acute lung injury | CHARITE UNIVERSITAETSMEDIZIN (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20110281805-A1 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY | CHARITE-UNIVERSITATSMEDIZIN BERLIN (DE) | 2011-11-17 | — | — | US | claimed |
| EP-2341938-A2 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY | Charité - Universitätsmedizin Berlin (DE) | 2011-07-13 | — | — | EP | claimed |
| WO-2010028845-A2 | USE OF AN ANG-(1-7) RECEPTOR AGONIST IN ACUTE LUNG INJURY | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2010-03-18 | — | — | WO | claimed |
| EP-2163259-A1 | Use of an Ang-(1-7) receptor agonist in acute lung injury | Charité-Universitätsmedizin Berlin (Charité) (DE) | 2010-03-17 | — | — | EP | claimed |
| US-20090221498-A1 | Use of Mas-G-Protein-Coupled Receptor Agonists in the Treatment of the Metabolic Syndrome, Its Components and its Complications | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2009-09-03 | — | — | US | claimed |
| EP-2018185-A1 | USE OF MAS-G-PROTEIN-COUPLED RECEPTOR AGONISTS IN THE TREATMENT OF THE METABOLIC SYNDROME, ITS COMPONENTS AND ITS COMPLICATIONS | Universidade Federal De Minas Gerais (BR) | 2009-01-28 | — | — | EP | claimed |
| WO-2007121546-A1 | USE OF MAS-G-PROTEIN-COUPLED RECEPTOR AGONISTS IN THE TREATMENT OF THE METABOLIC SYNDROME, ITS COMPONENTS AND ITS COMPLICATIONS | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2007-11-01 | — | — | WO | claimed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | disclosed |
| WO-2000068226-A1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | CYP11B1 163/4885CYP11B2 139/4885CYP17A1 2972/4885 |
| US-20160074466-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | AGT, REN, AGTR1 | CYP11B1 863/4885CYP11B2 957/4885CYP17A1 1657/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | CYP11B1 787/4885CYP11B2 820/4885CYP17A1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.